CStone Pharmaceuticals
Clinical trials sponsored by CStone Pharmaceuticals, explained in plain language.
A biopharmaceutical company focused on developing and commercializing cancer therapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Triple-Action antibody takes on advanced cancers Results expected Jan 2027 (estimated)
-
Can an Immune-Boosting antibody extend life in advanced lung cancer?
Disease control CompletedThis trial is investigating whether adding an experimental antibody called CS1001 to standard chemotherapy can help people with stage IV non-small cell lung cancer. The study compares the combination against chemotherapy alone in patients who have not yet received treatment for a…
Phase 3 • Sponsor: CStone Pharmaceuticals • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
New drug shows promise for rare stomach cancer in chinese patients
Disease control CompletedThis study looked at how safe and effective the drug avapritinib is for Chinese patients with a rare type of stomach cancer called gastrointestinal stromal tumor (GIST). Researchers observed 61 patients in real-world clinics, not in a controlled lab setting. The goal was to track…
Sponsor: CStone Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC